Introduction
============

Infection with the highly prevalent oncogenic human papillomaviruses (HPVs) (lifetime risk 70--80%), most notably with HPV types 16 and 18, is the primary cause of cervical cancer.[@b1] Past infection with *Chlamydia trachomatis* has also been linked to the development of cervical cancer, as demonstrated both in prospective seroepidemiological studies and PCR-based studies using archival cytological materials.[@b2; @b3; @b4; @b5]

The pathogenesis of *C trachomatis* in cervical intraepithelial neoplasia (CIN) remains unknown, but original observations[@b6] and independent, large-scale, longitudinal epidemiological studies[@b5] [@b7] [@b8] suggest that *C trachomatis* may be involved in cervical carcinogenesis. By inducing cervical metaplasia *C trachomatis* infection can provide target cells for acquisition of HPV (especially HPV type 18).[@b4] [@b6] On the other hand, by causing local immunoperturbation it may interfere with immune surveillance of persistent infection with hrHPV types.[@b9] These two alternatives are supported by cohort studies that show that *C trachomatis* infection is a risk factor for both incident hrHPV infection and persistence of hrHPV DNA.[@b10; @b11; @b12; @b13] However, evidence of *C trachomatis* infection increasing the risk of the development of CIN, among those with or without hrHPV infection at the baseline, is still missing. We used a joint cohort from two placebo-controlled trials of a quadrivalent HPV6/11/16/18 vaccine to examine the role of *C trachomatis* infection as an independent co-factor (possibly related to HPV acquisition) or HPV-dependent co-factor (related to HPV persistence) in the development of CIN.

Methods
=======

A cohort of 17 622 women aged 15--26 years was enrolled in two multinational trials which evaluated the efficacy and safety of a quadrivalent HPV6/11/16/18 virus-like particle vaccine (GARDASIL/SILGARD, Merck Sharp & Dohme, Whitehouse Station, New Jersey, USA).[@b14] [@b15] Both studies were approved by the institutional review boards (ethical review committees) at participating centres and informed consent was received from all the participants enrolled. The study designs and results of the primary hypotheses have been described, following the consort guidelines.[@b14] [@b15] The trials recruited healthy women who, at enrolment (day 1), reported having had 0--4 sex partners during their lifetime, except in Finland, where age over 17 years was used as an exclusion criterion.

As the study had no screening phase, the trials allowed the enrolment of women who had previously been or were currently infected with any of the HPV types known to infect the anogenital tract. All participants were tested for cervical cytological abnormalities, and *C trachomatis* at baseline and 12-monthly intervals in the FUTURE I and FUTURE II trials, respectively, for immediate treatment after which they were again eligible for the follow-up.[@b14] [@b15] In this study, the final cohort consisted of 8441 women who were randomised to the placebo arms of the two trials only, and followed approximately 3.7 years on average, with 25th and 75th percentiles of 3.5 and 3.9 years, respectively (maximum follow-up 4.9 years). *C trachomatis* serology was not performed.

Anogenital swabs collected at baseline, and all tissues collected from definitive therapy and excisions (including biopsy specimens) were tested with a PCR-based assay[@b16; @b17; @b18] for 14 HPV types, including the four vaccine types (ie, HPV6, 11, 16 and 18) and 10 other hrHPV types (HPV31, 33, 35, 39, 45, 51, 52, 56, 58 and 59) which are the most common hrHPV types in cervical cancer worldwide.[@b19] All tissue specimens, including those from definitive therapy and excision (including all biopsy specimens), were subjected to histopathological review by a blinded pathology panel.

This post hoc analysis was performed to assess the independent role of baseline *C trachomatis* in the development of CIN by comparing results from the HPV-stratified and HPV-adjusted analyses. The following CIN endpoints were evaluated: 1) CIN grade 2 (CIN2) due to any HPV type; 2) CIN2 related to a hrHPV type; 3) CIN grade 3 (CIN3) or adenocarcinoma in situ (AIS) due to any HPV type and 4) CIN3 or AIS related to a hrHPV type. High-risk types included the following 12 HPV types: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59. In our longitudinal follow-up study, risks of developing CIN2 and CIN3 or AIS were evaluated separately to distinguish early and later associations of *C trachomatis* with cervical intraepithelial neoplasia. Rates of these endpoints were summarised based on the number of women with a lesion per 100 person-years at risk.

Univariate and multivariate Cox models[@b20] were used to analyse the impact of baseline *C trachomatis* status on the end points. The univariate analysis stratified by HPV baseline status was first used for the evaluation of the impact of baseline *C trachomatis* status (positive vs negative) on the RR of developing CIN2 and CIN3 or AIS separately in baseline HPV-positive or HPV-negative individuals. Thereafter, the multivariate models adjusting for covariates such as baseline status (HPV positive or negative), age at study entry, number of lifetime sexual partners and smoking status (current smoker, former smoker, never smoked) were used to confirm the nature (HPV dependent or independent) of the *C trachomatis* associated risk. In the models pertaining to CIN endpoints due to any HPV type, HPV baseline status was defined based on positivity to HPV 16 or HPV 18. In the models of CIN endpoints, due to hrHPV types, HPV baseline status was based on positivity for any of the 12 tested types.

HRs and 95% CIs were calculated from both the univariate and multivariate models. In the latter the interaction between *C trachomatis* and baseline HPV status was assessed by including an interaction term in the Cox multivariate model. From this model, the impact of *C trachomatis* was estimated within each baseline HPV status (HPV negative and HPV positive) group to compare, at the baseline, the HPV-independent and HPV-dependent risk estimates.

Results
=======

Of the 8812 women randomised to the placebo arms, 8441 had non-missing data for *C trachomatis* infection at enrolment, with 354 of 8441 (4.2%) positive for *C trachomatis*, and 2629 (31.1%) positive for hrHPV DNA at baseline. The age distribution, age at sexual debut and lifetime number of sex partners were similar between the *C trachomatis*-positive and *C trachomatis*-negative women ([table 1](#tbl1){ref-type="table"}). Smoking was more common among the former (32.8% vs 26.8%). The frequency of any squamous intraepithelial lesions, HPV16/18 infection and infections with ≥1 of 14 tested HPV types was twofold higher among baseline *C trachomatis*-positive women compared with *C trachomatis* negative women ([table 1](#tbl1){ref-type="table"}).

###### 

Baseline characteristics of the study population

                                                                                         *Chlamydia trachomatis* positive at day 1 (N=354)   *C trachomatis* negative at day 1 (N=8087)
  -------------------------------------------------------------------------------------- --------------------------------------------------- --------------------------------------------
  Mean age (years) ±SD                                                                   20.2±2.0                                            20.0±2.1
  Age at first sexual intercourse ±SD (among non-virgins)                                16.5±1.8                                            16.7±1.9
  Median lifetime number of sexual partners (IQR)                                        2 (2--3)                                            2 (1--3)
  Current smoker                                                                         116/354 (32.8%)                                     2166/8087 (26.8%)
  Any squamous intraepithelial neoplasia present[\*](#table-fn1){ref-type="table-fn"}    69/337 (20.5%)                                      860/7854 (10.9%)
  Positive (by PCR) to ≥1 of 14[†](#table-fn2){ref-type="table-fn"} tested HPV types     208/354 (58.8%)                                     2540/8087 (31.4%)
  Positive (by PCR) to ≥1 of 12[‡](#table-fn3){ref-type="table-fn"} tested hrHPV types   204/354 (57.6%)                                     2425/8087 (30.0%)
  Positive (by PCR) to HPV16 and/or 18                                                   81/354 (22.9%)                                      884/8087 (10.9%)

Denominator includes only those women with a satisfactory day 1 Pap test result.

Includes HPV6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59.

Includes HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59.

hrHPV, high-risk HPV.

Crude (univariate analysis) HRs suggested that women with *C trachomatis* at baseline were about two times more likely to develop CIN2 than those without ([table 2](#tbl2){ref-type="table"}). After adjusting (multivariate analysis) for HPV16/18 status, age at study entry, number of lifetime sexual partners and smoking status, women with *C trachomatis* at baseline were 1.78 times more likely to develop CIN2 due to any HPV type (p=0.002, [table 2](#tbl2){ref-type="table"}) than those without *C trachomatis*. Finally, in the multivariate analysis among women with HPV16/18 infection at baseline, those with *C trachomatis* at baseline were 1.82 times more likely to develop CIN2 due to any HPV type compared with those without (p=0.030, [table 2](#tbl2){ref-type="table"}). A similar point estimate (HR 1.74, p=0.033, [table 2](#tbl2){ref-type="table"}) was observed among those without HPV16/18 infection. In corresponding, multivariate analyses among women with at least one of the 12 tested hrHPV types at baseline, those with *C trachomatis* were 1.59 times more likely to develop CIN2 related to one of the 12 tested hrHPVs compared with those without (p=0.033, [table 2](#tbl2){ref-type="table"}), among baseline hrHPV negative women, the point estimate even if not statistically significant was not materially different (HR 1.35).

###### 

Multivariate and univariate analysis for risk (HR) of developing cervical intraepithelial neoplasia grade 2 (CIN2) according to baseline *Chlamydia trachomatis* and high-risk human papillomavirus (hrHPV) DNA status

                                   N      *C trachomatis* positive at day 1 (N=354)   *C trachomatis* negative at day 1 (N=8087)   Multivariate model   Univariate model                                                                    
  -------------------------------- ------ ------------------------------------------- -------------------------------------------- -------------------- ------------------ ----- ------ --------------------- ------- --------------------- ----------
  CIN2 due to any HPV type                                                                                                                                                                                                                  
   Total                           8441   354                                         32                                           2.76                 8087               330   1.18   1.78 (1.23 to 2.58)   0.002   2.28 (1.58 to 3.28)   \<0.0001
    Negative for HPV16 and 18      7382   268                                         16                                           1.76                 7114               226   0.91   1.74 (1.05 to 2.90)   0.033   1.86 (1.12 to 3.09)   0.017
    Positive for HPV16 and/or 18   965    81                                          15                                           6.47                 884                101   3.67   1.82 (1.06 to 3.14)   0.030   1.74 (1.01 to 3.00)   0.045

                                                                                   N      n     No of women with a CIN2 lesion due to hrHPV type[§](#table-fn7){ref-type="table-fn"}   Rate[\*](#table-fn4){ref-type="table-fn"}   n      No of women with a CIN2 lesion due to hrHPV type[§](#table-fn7){ref-type="table-fn"}   Rate[\*](#table-fn4){ref-type="table-fn"}   HR[†](#table-fn5){ref-type="table-fn"} (95% CI)   p-value[‡](#table-fn6){ref-type="table-fn"}   HR[†](#table-fn5){ref-type="table-fn"} (95% CI)   p-value[‡](#table-fn6){ref-type="table-fn"}
  -------------------------------------------------------------------------------- ------ ----- -------------------------------------------------------------------------------------- ------------------------------------------- ------ -------------------------------------------------------------------------------------- ------------------------------------------- ------------------------------------------------- --------------------------------------------- ------------------------------------------------- ---------------------------------------------
  CIN2 due to hrHPV[§](#table-fn7){ref-type="table-fn"} type                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Total                                                                           8441   354   29                                                                                     2.49                                        8087   296                                                                                    1.06                                        1.55 (1.05 to 2.30)                               0.028                                         2.28 (1.56 to 3.34)                               \<0.0001
    Negative for all 12 tested[§](#table-fn7){ref-type="table-fn"} hrHPV types     5689   143   4                                                                                      0.8                                         5546   114                                                                                    0.58                                        1.35 (0.50 to 3.67)                               0.554                                         1.33 (0.49 to 3.59)                               0.579
    Positive for ≥1 of 12 tested[§](#table-fn7){ref-type="table-fn"} hrHPV types   2629   204   24                                                                                     3.75                                        2425   179                                                                                    2.26                                        1.59 (1.04 to 2.44)                               0.033                                         1.63 (1.07 to 2.50)                               0.024

N: Total number of women with non-missing Chlamydia status and respective PCR status and at least one follow-up visit.

n: Number of women with positive/negative Chlamydia status and positive/negative PCR status and at least one follow-up visit.

Number of women with a lesion per 100 person-years at risk.

HR associated with being positive versus negative to Chlamydia at baseline for each model. For the 'univariate---total' estimates, HR is calculated using the full data. For the 'univariate---negative/positive' estimates, HR is calculated using data from each stratified HPV baseline status group. For the 'multivariate---total' estimates, HR is calculated after adjusting for HPV baseline status (positive or negative), age at study entry, number of lifetime sexual partners and smoking status (current smoker, former smoker, never smoked). Interactions between baseline HPV status and Chlamydia status were tested and proved to be insignificant (p-values of interactions are 0.905 and 0.768 in the models of CIN2 due to any HPV type and CIN2 due to any hrHPV type, respectively). For the 'multivariate---negative/positive' estimates, HR is estimated within each HPV baseline status group after including the interaction term between baseline Chlamydia status and baseline HPV status and adjusting for age at study entry, number of lifetime sexual partners and smoking status.

p Value shows how significantly the estimated HRs differ from 1.

Includes HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59.

When the end points were any HPV- or hrHPV-positive CIN3 or AIS, the point estimates in the total univariate analysis were statistically significant (HR for those with vs those without *C trachomatis*=1.74, 95% CI: 1.10 to 2.74, p=0.017, 1.82, 95% CI: 1.15 to 2.87, p=0.010, respectively, [table 3](#tbl3){ref-type="table"}). However, in the multivariate analysis among HPV16/18, the positives also approached unity (HR for those with vs those without *C trachomatis*=1.19, 95% CI: 0.62 to 2.28, p=0.601, [table 3](#tbl3){ref-type="table"}). This was true also for the 12 hrHPV associated point estimates (HR for those with vs those without *C trachomatis*=1.05, 95% CI: 0.63 to 1.75, p=0.851, [table 3](#tbl3){ref-type="table"}).

###### 

Multivariate and univariate analysis for risk (HR, HR) of developing cervical intraepithelial neoplasia grade 3 (CIN3) or adenocarcinoma in situ (AIS) according to baseline *Chlamydia trachomatis* and high-risk human papillomavirus (hrHPV) DNA status

                                   N      *C trachomatis* positive at day 1 (N=354)   *C trachomatis* negative at day 1 (N=8087)   Multivariate model   Univariate model                                                                    
  -------------------------------- ------ ------------------------------------------- -------------------------------------------- -------------------- ------------------ ----- ------ --------------------- ------- --------------------- -------
  CIN3/AIS due to any HPV type                                                                                                                                                                                                              
   Total                           8441   354                                         20                                           1.71                 8087               267   0.96   1.31 (0.83 to 2.06)   0.253   1.74 (1.10 to 2.74)   0.017
    Negative for HPV16 and 18      7382   268                                         10                                           1.09                 7114               163   0.66   1.44 (0.76 to 2.73)   0.265   1.61 (0.85 to 3.05)   0.146
    Positive for HPV16 and/or 18   965    81                                          10                                           4.3                  884                103   3.71   1.19 (0.62 to 2.28)   0.601   1.15 (0.60 to 2.21)   0.666

                                                                                    N      n     No of women with a CIN3/AIS lesion due to hrHPV type[§](#table-fn11){ref-type="table-fn"}   Rate[\*](#table-fn8){ref-type="table-fn"}   n      No of women with a CIN3/AIS lesion due to hrHPV type[§](#table-fn11){ref-type="table-fn"}   Rate[\*](#table-fn8){ref-type="table-fn"}   HR[†](#table-fn9){ref-type="table-fn"} (95% CI)   p-value[‡](#table-fn10){ref-type="table-fn"}   HR[†](#table-fn9){ref-type="table-fn"} (95% CI)   p-value[‡](#table-fn10){ref-type="table-fn"}
  --------------------------------------------------------------------------------- ------ ----- ------------------------------------------------------------------------------------------- ------------------------------------------- ------ ------------------------------------------------------------------------------------------- ------------------------------------------- ------------------------------------------------- ---------------------------------------------- ------------------------------------------------- ----------------------------------------------
  CIN3/AIS due to hrHPV[§](#table-fn11){ref-type="table-fn"} type                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
   Total                                                                            8441   354   20                                                                                          1.71                                        8087   256                                                                                         0.92                                        1.10 (0.69 to 1.76)                               0.693                                          1.82 (1.15 to 2.87)                               0.010
    Negative for all 12 tested[§](#table-fn11){ref-type="table-fn"} hrHPV types     5689   143   3                                                                                           0.6                                         5546   77                                                                                          0.39                                        1.43 (0.45 to 4.55)                               0.540                                          1.50 (0.47 to 4.77)                               0.488
    Positive for ≥1 of 12 tested[§](#table-fn11){ref-type="table-fn"} hrHPV types   2629   204   16                                                                                          2.48                                        2425   179                                                                                         2.25                                        1.05 (0.63 to 1.75)                               0.851                                          1.09 (0.65 to 1.81)                               0.750

N: Total number of women with non-missing Chlamydia status and respective PCR status and at least one follow-up visit.

n: Number of women with positive/negative Chlamydia status and positive/negative PCR status and at least one follow-up visit.

Number of women with a lesion per 100 person-years at risk.

HR associated with being positive versus negative to Chlamydia at baseline for each model. For the 'univariate---total' estimates, HR is calculated using the full data. For the 'univariate---negative/positive' estimates, HR is calculated using data from each stratified HPV baseline status data. For the 'multivariate---total' estimates, HR is calculated after adjusting for HPV baseline status (positive or negative), age at study entry, number of lifetime sexual partners, and smoking status (current smoker, former smoker, never smoked). Interactions between baseline HPV status and Chlamydia status were tested and proven to be insignificant (P-values of interactions are 0.683 and 0.628 in the models of CIN3/AIS due to any HPV type and CIN3/AIS due to any hrHPV type, respectively). For the 'multivariate---negative/positive' estimates, HR is estimated within each HPV baseline status group after including the interaction term between baseline Chlamydia status and baseline HPV status and adjusting for age at study entry, number of lifetime sexual partners, and smoking status.

p Value shows how significantly the estimated HRs differ from 1.

Includes HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59.

Discussion
==========

Our results suggest that if infection with *C trachomatis* plays an independent co-factor role in the development of cervical neoplasia,[@b21] [@b22] the effect is likely to take place at an early stage of cervical carcinogenesis and/or restricted to some cases only. Our data are well in line with previous reports. Studies showing an effect of *C trachomatis* on late outcomes, such as cervical cancer, have either used long follow-up times or the highest point estimates have been obtained for cases with longest lag time between *C trachomatis* exposure and the outcome.[@b2; @b3; @b4; @b5]

The study has several strengths. This large cohort study enrolled a diverse population of young women participating in developed and developing countries. High diagnostic accuracy for CIN determination was provided by a panel of expert pathologists. In addition, there was well controlled, sensitive testing for HPV DNA and for baseline *C trachomatis* infection by PCR. Though this was a relatively large study, the quadrivalent vaccine clinical trials were neither designed nor powered to examine the role of *C trachomatis* infection as a co-factor in the development of CIN. Other limitations of this post hoc analysis study include the limited follow-up time, and the fact that residual confounding by unknown factors could not be eliminated. Overall, any effects of *C trachomatis* were expected to be seen on the earliest CIN endpoints with the most statistical power.

The questions of which of the two infections, HPV or *C trachomatis*, has to occur first, and whether the latter increases the risk of acquiring HPV could not be fully answered with the obtained results. The fact that the *C trachomatis* associated relative risk (RR) of developing CIN2 was statistically significant albeit comparable both before and after acquisition of HPV16/18 (independently of baseline HPV positivity) suggests that the order of the two infections is not important in cervical carcinogenesis. Because of this result (independent risk factor role of *C trachomatis*) and due to the study setting (screening and treatment of *C trachomatis* infection during the active follow-up), it is not really possible to make even indirect inferences on the possible increased acquisition of HPV infection following *C trachomatis* infection. If *C trachomatis* had been proved to be a risk factor only in baseline HPV negatives or in baseline HPV positives, the increased acquisition hypothesis could have been verified or falsified.

Several cohort studies have indicated that *C trachomatis* exposure increases the tendency for HPV infection to persist.[@b10; @b11; @b12; @b13] This effect on persistence could translate to an associated increased risk for cervical cancer. An analysis of the HPV-stratified and HPV-adjusted risk estimates obtained both in the univariate and multivariate analyses (with very limited residual confounding from hrHPVs because of the highly sensitive HPV PCR) suggests that the *C trachomatis* associated RR of developing CIN2 is comparable both before and after acquisition of HPV. Furthermore, no interaction between the two microorganisms was observed. Thus, *C trachomatis* may not act in the cervical carcinogenesis by promotion of persistent HPV infection.

In the present study, the observation that baseline *C trachomatis* positivity was associated with CIN2 but not with CIN3 suggests that *C trachomatis* infection might facilitate the development of early cervical lesions although there is a possibility that the difference in results for CIN2 and CIN3 might be due to chance. On the other hand, a proportion of both CIN2 and CIN3 lesions regress. This, and the fact that *C trachomatis* in other longitudinal studies has been associated with early stages of lesions developing to cervical cancer[@b2; @b3; @b4; @b5; @b6] suggest that *C trachomatis* may have an early role in cervical carcinogenesis in a proportion of cases. The pathobiology of its possible role, however, remains open.

We do not know for how long the *C trachomatis*-positive individuals had been positive before entering the study. Testing and treatment of *C trachomatis* infection during the active follow-up, as well as the relatively small number of patients, also reduced the power of our study in assessing *C trachomatis* associated risks, especially the risk of CIN3 and AIS, longitudinally. The observed CIN2 association could be spurious and due to confounding by the relationship between *C trachomatis* and infection with HPV types that have not been tested for. However, the difference in the oncogenicity between the tested and non-tested hrHPV types, and the low prevalence of the latter,[@b23] makes this unlikely.

Further studies based on larger cohorts with longitudinal follow-up in relation to the *C trachomatis* acquisition and a thorough evaluation of temporal relationships of infections with hrHPV types, *C trachomatis* and cervical neoplasia are needed to demonstrate whether in some situations *C trachomatis* sets the stage for cervical carcinogenesis.

###### Key Messages

-   We conducted a longitudinal, 4-year follow-up study on the role of *Chlamydia trachomatis* as a risk factor for cervical intraepithelial neoplasia (CIN) in a sizeable cohort of 8441 placebo vaccinated 15--26-year-old women.

-   Baseline *C trachomatis* PCR positivity was an independent, albeit moderate (HR 1.8) risk factor for the development of CIN2 with materially indistinguishable point estimates in both baseline HPV16/18 positives and HPV16/18 negatives.

-   *C trachomatis* may be involved only in the early stages of cervical carcinogenesis as no increased risk associated with *C trachomatis* was found for CIN3. The pathobiology of its possible role, however, remains open.

-   Further studies based on larger cohorts with longitudinal follow-up in relation to the *C trachomatis* acquisition and a thorough evaluation of temporal relationships of infections with hrHPV types, *C trachomatis* and cervical neoplasia are needed to demonstrate whether and how in some situations *C trachomatis* sets the stage for cervical carcinogenesis.
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